PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
By Ramandeep Singh, U. Manjunatha, H. Boshoff, Y. Ha, P. Niyomrattanakit, Richard Ledwidge, C. Dowd, I. Lee, P. Kim, Liang Zhang and 4 more. Science, 2008
622 citations recorded by the source corpus.
Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis. These prodrugs require intracellular activation for their biological function. We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro). When derivatives of PA-824 were used, the amount of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb). Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compounds. Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug. Thus, these compounds may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.
Subfields: Infectious Diseases, Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/6bd10037dce17648f24a33b83b19fa5c574ca100
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- The spectrum of latent tuberculosis: rethinking the goals of prophylaxis (2009, positive): “Instead of simply inhibiting an enzymatic activity to block a metabolic process, effective drugs might, for instance, have to trigger build-up of toxic intermediates, cause the release of bactericidal metabolites (for example, nitric oxid”